You can buy or sell MTEM and other stocks, options, ETFs, and crypto commission-free!
Molecular Templates, Inc. Common Stock, also called Molecular Templates, is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. Read More Its product pipeline includes MT-3724, TAK-169, MT-5111, and MT-6035. The company was founded on October 17, 2001 and is headquartered in Austin, TX.
52 Week High
52 Week Low
Yahoo FinanceMay 13
Molecular Templates, Inc. Reports First Quarter 2019 Financial Results
AUSTIN, Texas, May 13, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today reported financial results for the first quarter of 2019. As of March 31, 2019, Molecular’s cash and investments totaled $84 million, and is expected to fund operations int...
Yahoo FinanceMay 6
Will Molecular Templates (MTEM) Report Negative Q1 Earnings? What You Should Know
The market expects Molecular Templates (MTEM) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
-$0.22 per share
-$0.17 per share